Melbourne, Australia – Acrux (ASX:ACR) has today announced that Acrux and Eli Lilly and Company have mutually agreed to terminate their licensing agreement for Axiron®. Termination of the license in the US is effective immediately and termination of license outside the US will be effective 90 days thereafter. Global rights to the product will revert to Acrux.
well that explains quite a lot. Wonder how long management were aware that this was in the pipeline!. it surely wasn't an overnight thing - maybe some explanation should have been provided earlier as to what was happening.
event though the rights revert back to ACR lets face it their marketing not the best so will be a hard sell from here IMO and wonder if this is factored out of the calculations for staff bonuses!
just keeps getting better (in a sarcastic voice).
Add to My Watchlist
What is My Watchlist?
